# US 2007/0009598 A1 · Sustained-release microgranules containging gingko biloba extract and the process for manufacturing these

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2007/0009598 A1
- Document ID: US20070009598A1
- Status: Published application
- Kind: A1
- Application number: 10/574,923
- Filed: 2004-10-11
- Published: 2007-01-11
- Earliest claimed: 2003-10-10
- Assignees: Ethypharm
- Inventors: Dominique Marechal
- Web page: https://patentgrep.com/patent/US20070009598A1

## CPC

- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61K 9/5078: {with drug-free core}
- A61K 9/5089: {Processes}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

Sustained release microgranules containing a Gingko Biloba extract, wherein the release of total flavone glycosides having the following profile of dissolution rates measured at 37.0° C.±0.5° C., with a Dissolution Test Apparatus I (Basket method at 100 rpm, 900 mL of purified water UV Detection: 272 nm):
T (h)
DISSOLUTION (w/w)
0.5 hour
≦45%
2 hours
<75%
8 hours
>60%

### Claim 31 (depends on 30)

Sustained release microgranules according to claim 30, wherein the profile is as follows:
T (h)
Dissolution (w/w)
0.5
hour
5-45%
2
hours
30-70%
8
hours
>60%

### Claim 32 (depends on 30)

Sustained release microgranules according to claim 30 comprising:
a neutral core coated with a layer containing Gingko Biloba extract with at least one pharmaceutically acceptable excipient,
an optional water-repellent layer, coating said core, comprising at least a polymer or a thermoplastic excipient,
an outer polymeric layer which sustain the release of said extract from the active core.

### Claim 33 (depends on 32)

Sustained release microgranules according to claim 32, wherein the neutral core consists of a substance chosen from sugar, starch, mannitol, sorbitol, xylitol, cellulose, talc and mixtures thereof.

### Claim 34 (depends on 33)

Sustained release microgranules according to claim 33, wherein the neutral core consists of a starch/sucrose core in 80/20 mass ratios.

### Claim 35 (depends on 30)

Sustained release microgranules according to claim 30, wherein the Gingko Biloba extract contains up to 40% by weight of flavonoids, and up to 10% by weight of terpenes.

### Claim 36 (depends on 35)

Sustained release microgranules according to claim 35, wherein the Gingko Biloba extract preferably contains up to 24% by weight of flavonoids, and up to 6% by weight of terpenes.

### Claim 37 (depends on 32)

Sustained release microgranules according to claim 32, wherein the layer containing the Gingko Biloba extract contains at least one pharmaceutically acceptable excipient, selected from the group comprising a binder, an antistatic agent or a lubricant.

### Claim 38 (depends on 37)

Sustained release microgranules according to claim 37, wherein the binder is selected from the group consisting of cellulosic polymers, acrylic polymers, polyacrylate, povidones, copovidones, polyvinylalcohols, shellac, alginic acid, sodium alginate, starch, pregelatinized starch, sucrose and its derivatives, guar gum, polyethylene glycol.

### Claim 39 (depends on 38)

Sustained release microgranules according to claim 38, wherein the binder is used in proportions of at most about 50% by weight of Gingko Biloba extract.

### Claim 40 (depends on 37)

Sustained release microgranules according to claim 37, wherein the antistatic agent, which can be used as flow aid, is selected from the group consisting of micronised or non micronised talc, fumed silica, colloidal silica, precipitated silica and mixtures thereof.

### Claim 41 (depends on 40)

Sustained release microgranules according to claim 40, wherein the antistatic agent is used in proportions of at most 5% by weight relative to the weight of said granules of Gingko Biloba.

### Claim 42 (depends on 37)

Sustained release microgranules according to claim 37, wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, micronised polyoxyethyleneglycol, leukine, sodium benzoate and mixtures thereof.

### Claim 43 (depends on 42)

Sustained release microgranules according to claim 42, wherein the amount of lubricant is from 0 to 3% by weight, based on the weight of the granules.

### Claim 44 (depends on 32)

Sustained release microgranules according to claim 32, wherein the intermediate water-repellent layer comprises at least a polymer or a thermoplastic excipient.

### Claim 45 (depends on 44)

Sustained release microgranules according to claim 44, wherein the polymer is selected from the group consisting of cellulosic polymers, acrylic polymers, polyacrylate, povidones, copovidones, polyvinylalcohols, shellac, alginic acid, sodium alginate, starch, pregelatinized starch, sucrose and its derivatives, guar gum, polyethylene glycol.

### Claim 46 (depends on 32)

Sustained release microgranules according to claim 32, wherein the outer polymeric layer contains at least one coating agent selected from the group consisting of cellulosic polymers, acrylic polymers, shellac and mixtures thereof.

### Claim 47 (depends on 46)

Sustained release microgranules according to claim 46, wherein the cellulosic polymer is selected among ethylcellulose, hydroxypropylcellulose and/or hydroxypropylmethylcellulose.

### Claim 48 (depends on 46)

Sustained release microgranules according to claim 46, wherein the acrylic polymer is selected from insoluble acrylate ammonio-methacrylate copolymer, polyacrylate, or methacrylic copolymers, and combinations thereof.

### Claim 49 (depends on 48)

Sustained release microgranules according to claim 48, wherein the outer polymeric layer additionally contains a plasticizer, a surfactant, an antistatic agent and/or a lubricant.

### Claim 50 (depends on 49)

Sustained release microgranules according to claim 49, wherein the plasticizer is selected in the group consisting of dibutyl sebacate, triacetine, triethylacetate, triethylcitrate, ethylphtalate, or mixtures thereof.

### Claim 51 (depends on 50)

Sustained release microgranules according to claim 50, wherein the plasticizer is used in proportions of at most about 30% by weight of the coating polymers.

### Claim 52 (depends on 37)

Sustained release microgranules according to claim 37, wherein the antistatic agent is selected from the group comprising micronised or non micronised talc, fumed silica, colloidal silica, precipitated silica and mixtures thereof.

### Claim 53 (depends on 52)

Sustained release microgranules according to claim 52, wherein the antistatic agent is used in proportions of at most about 10%, by weight.

### Claim 54 (depends on 30)

Process for the preparation of sustained release microgranules according to claim 30, comprising the successive steps consisting of:
applying over a neutral core, a layer comprising Gingko Biloba extract, and at least one pharmaceutical excipient.
coating said core with an intermediate layer over the thus obtained granules by spraying thereon a suspension, or a solution comprising a polymer or a thermoplastic excipient
coating the thus coated granules with an outer layer by spraying a suspension, a dispersion or a solution of a sustained-release coating composition,
drying the thus obtained coated granules.

### Claim 55 (depends on 31)

Process for the preparation of sustained release microgranules according to claim 31, comprising the successive steps consisting of:
applying over a neutral core, a layer comprising Gingko Biloba extract, and at least one pharmaceutical excipient.
coating said core with an intermediate layer over the thus obtained granules by spraying thereon a suspension, or a solution comprising a polymer or a thermoplastic excipient
coating the thus coated granules with an outer layer by spraying a suspension, a dispersion or a solution of a sustained-release coating composition,
drying the thus obtained coated granules.

### Claim 56 (depends on 32)

Process for the preparation of sustained release microgranules according to claim 32, comprising the successive steps consisting of:
applying over a neutral core, a layer comprising Gingko Biloba extract, and at least one pharmaceutical excipient.
coating said core with an intermediate layer over the thus obtained granules by spraying thereon a suspension, or a solution comprising a polymer or a thermoplastic excipient
coating the thus coated granules with an outer layer by spraying a suspension, a dispersion or a solution of a sustained-release coating composition,
drying the thus obtained coated granules.

### Claim 57 (depends on 54)

Process for the preparation of sustained release microgranules according to claim 54, wherein the layer is applied over the neutral cores by spraying a coating alcoholic or aqueous alcoholic solution containing the Gingko Biloba extracts and the excipient.

### Claim 58 (depends on 57)

Process for the preparation of sustained release microgranules according to claim 57, wherein the alcoholic or aqueous alcoholic solution contains isopropylic alcohol.

### Claim 59 (depends on 57)

Process for the preparation of sustained release microgranules according to claim 57, wherein the layer applied over the neutral cores is a 10% w/w binding solution of shellac dissolved in isopropyl alcohol.

### Claim 60 (depends on 54)

Process for the preparation of sustained release microgranules according to claim 54, wherein the outer coating layer is a water dispersion of ethylcellulose at 16% w/w containing 25% w/w of dibutyl sebacate versus dry polymer.
